Valuation: Titan Pharmaceuticals, Inc.

Market Cap 6.13M 5.35M 5.05M 4.59M 8.59M 588M 8.63M 60.48M 23.34M 299M 23.04M 22.52M 963M P/E 2023
-1.11x
P/E 2024 -0.62x
Enterprise Value 3.3M 2.88M 2.72M 2.47M 4.62M 317M 4.64M 32.56M 12.57M 161M 12.4M 12.13M 518M EV / Sales 2023
0.11x
EV / Sales 2024 -
Free-Float
-
Yield 2023 *
-
Yield 2024 -

Financials

2023 2024
Net sales 184K 160K 152K 138K 258K 17.66M 259K 1.81M 700K 8.98M 691K 676K 28.88M -
Net income -5.57M -4.86M -4.59M -4.16M -7.8M -534M -7.83M -54.93M -21.2M -272M -20.92M -20.46M -874M -4.71M -4.1M -3.87M -3.52M -6.59M -452M -6.62M -46.41M -17.91M -230M -17.68M -17.29M -739M
Net Debt -6.2M -5.4M -5.1M -4.63M -8.68M -594M -8.71M -61.1M -23.58M -302M -23.27M -22.75M -972M -2.83M -2.47M -2.33M -2.12M -3.97M -272M -3.98M -27.92M -10.77M -138M -10.63M -10.4M -444M
Logo Titan Pharmaceuticals, Inc.
Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
Employees
-
Sector
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!